Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vadim S Koshkin

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Current Oncology Reports|April 13, 2018
Emerging Role of Immunotherapy in Advanced Urothelial CarcinomaVadim S Koshkin, Petros Grivas
Med (New York, N.Y.)|December 21, 2023
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancerXiaolin Zhu, Vadim S Koshkin
Expert Opinion on Pharmacotherapy|April 27, 2016
Emerging therapeutics in refractory renal cell carcinomaVadim S Koshkin, Brian I Rini
Therapeutic Advances in Urology|December 22, 2018
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trialsVadim S Koshkin, Eric J Small
European Urology Focus|May 26, 2024
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment LandscapeJason R Brown, Vadim S Koshkin
Current Treatment Options in Oncology|July 10, 2023
Perioperative Immunotherapy in Muscle-Invasive Bladder CancerAmisha Singh, Appledene S Osbourne, Vadim S Koshkin
Translational Andrology and Urology|November 22, 2021
Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature reviewVadim S Koshkin, Appledene S Osbourne, Petros Grivas
Frontiers in Oncology|November 7, 2022
HER2 expression in urothelial carcinoma, a systematic literature reviewEmilie Scherrer, Ashley Kang, Lisa M Bloudek, et al.
Academic Radiology|April 28, 2012
CAD-associated reader error in CT colonographyVadim S Koshkin, J Louis Hinshaw, Kristen Wroblewski, et al.
Journal of Voice : Official Journal of the Voice Foundation|January 19, 2023
Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab TreatmentAntonia Lagos-Villaseca, Vadim S Koshkin, Maxime J Kinet, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Current Oncology Reports|April 13, 2018
Emerging Role of Immunotherapy in Advanced Urothelial CarcinomaVadim S Koshkin, Petros Grivas
Med (New York, N.Y.)|December 21, 2023
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancerXiaolin Zhu, Vadim S Koshkin
Expert Opinion on Pharmacotherapy|April 27, 2016
Emerging therapeutics in refractory renal cell carcinomaVadim S Koshkin, Brian I Rini
Therapeutic Advances in Urology|December 22, 2018
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trialsVadim S Koshkin, Eric J Small
European Urology Focus|May 26, 2024
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment LandscapeJason R Brown, Vadim S Koshkin
Current Treatment Options in Oncology|July 10, 2023
Perioperative Immunotherapy in Muscle-Invasive Bladder CancerAmisha Singh, Appledene S Osbourne, Vadim S Koshkin
Translational Andrology and Urology|November 22, 2021
Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature reviewVadim S Koshkin, Appledene S Osbourne, Petros Grivas
Frontiers in Oncology|November 7, 2022
HER2 expression in urothelial carcinoma, a systematic literature reviewEmilie Scherrer, Ashley Kang, Lisa M Bloudek, et al.
Academic Radiology|April 28, 2012
CAD-associated reader error in CT colonographyVadim S Koshkin, J Louis Hinshaw, Kristen Wroblewski, et al.
Journal of Voice : Official Journal of the Voice Foundation|January 19, 2023
Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab TreatmentAntonia Lagos-Villaseca, Vadim S Koshkin, Maxime J Kinet, et al.
Pageof 10